(Reuters) -London-based buyout firm CapVest Partners is in talks to acquire a majority stake in German drugmaker Stada Arzneimittel, Bloomberg News reported on Tuesday.
The deal would value Stada Arzneimittel at about 10 billion euros ($11.75 billion) including debt, the report said, citing unnamed sources.
CapVest is in discussions with Stada’s private equity owners, Bain Capital and Cinven, regarding the transaction. Stada has also been exploring a potential listing, the report said.
CapVest declined comment, while Stada did not immediately respond to a Reuters’ request for comment.
Stada, known for its cold medicine Grippostad, sunscreen Ladival and the cough syrup Silomat in March, postponed a planned IPO in Frankfurt due to market volatility.
Bankers advising Bain Capital and Cinven recommended against proceeding with the listing at that time, Reuters reported.
($1 = 0.8511 euros)
(Reporting by Angela Christy in Bengaluru; Editing by Tasim Zahid)
